CLRB
CLRB
NASDAQ · Biotechnology

Cellectar Biosciences Inc

$2.58
+0.04 (+1.57%)
As of Apr 1, 4:16 PM ET ·
Financial Highlights (FY 2025)
Revenue
1.64M
Net Income
-247,177
Gross Margin
55.2%
Profit Margin
-15.1%
Rev Growth
+20.7%
D/E Ratio
0.09
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 55.2% 55.2% 55.2%
Operating Margin -13.8% -13.4% -14.4%
Profit Margin -15.1% -15.4% -16.8%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 1.64M 1.62M 1.37M
Gross Profit 906.4K 895.4K 755.0K
Operating Income -227,106 -217,887 -197,493
Net Income -247,177 -249,222 -229,259
Gross Margin 55.2% 55.2% 55.2%
Operating Margin -13.8% -13.4% -14.4%
Profit Margin -15.1% -15.4% -16.8%
Rev Growth +20.7% +12.0% +3.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 725.4K 769.8K 655.7K
Total Equity 8.16M 7.21M 8.65M
D/E Ratio 0.09 0.11 0.08
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -331,691 -310,875 -283,649
Free Cash Flow -127,219 -197,557 -123,470